Search…
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
Search...
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
Home
>
Latest
Lates News
23/10/2026
Apple wins copyright case over 'Servant' with director M. Night Shyamalan.
Latest
3 m ago
Brent crude oil broke through $113 per barrel, up 3.87% on the day.
3 m ago
London stocks fell on the 22nd.
4 m ago
JPMorgan: A merger with Tesla could be SpaceX's ticket into the S&P 500
6 m ago
The Nagqu Military Sub-district of the Tibet Military District dispatched 98 officers and soldiers to the earthquake-stricken area.
11 m ago
Moderna (MRNA.O) fell nearly 25% at one point during intraday trading on Thursday, while Merck (MRK.N) dropped 3.7%. Trial data for an experimental cancer vaccine jointly developed by the two companies was suspected to have been published ahead of schedule on the medical website Oncology Central and was subsequently taken down; it had been scheduled for release on Saturday at the European Society for Medical Oncology (ESMO) Congress. According to the briefly disclosed data, the vaccine used in combination with Merck's anticancer drug Keytruda can reduce the risk of melanoma recurrence or death. The two companies had previously announced that the Phase 3 trial met its primary goals but had not yet published detailed results.
See all latest